FOLH1 and prostate cancer: However, due to its wide application for the PET imaging of prostate cancer, the FDA-approved [68Ga]Ga-PSMA-11, which has a similar structure, is preferred, particularly because new kit preparations have been approved by the FDA: illuccix® (Telix Pharmaceuticals, Inc., Fishers, Indiana, USA) in December 2021 [15] and Locametz® (AAA, a Novartis company, Millburn, NJ, USA) simultaneously to PluvictoTM [16].